直接口服抗凝药时代儿童静脉血栓栓塞症的治疗
直接口服抗凝药利伐沙班和达比加群新近获批用于儿童静脉血栓栓塞症的治疗和预防,标志着儿科抗凝管理的复兴。本文作者分享日常实践中血液科医生可能遇到的4个管理场景的经验,涵盖适应症、特殊人群、实验室监测、抗凝药转换、药物相互作用、围手术期管理和抗凝逆转等主题。
要点
- 利伐沙班和达比加群新近获批用于儿童静脉血栓栓塞症的治疗和预防。
- 直接口服抗凝药具有口服给药、儿童友好剂型和显著减少监测的优势。
- 直接口服抗凝药在儿科患者中的累积经验稀少,尤其对合并慢性疾病者。
核心结论
- 直接口服抗凝药利伐沙班和达比加群新近获批用于儿童静脉血栓栓塞症的治疗和预防,标志着儿科抗凝管理的复兴。
- 直接口服抗凝药在儿科患者中的累积经验稀少,尤其对合并慢性疾病者,临床医生常需依赖自身经验并从成人数据外推。
研究设计与样本
- 本文为作者分享日常实践中管理4个场景的经验,非系统研究。
主要发现
- 直接口服抗凝药具有口服给药、儿童友好剂型和显著减少监测的优势,优于标准抗凝药(肝素类、磺达肝癸钠和维生素K拮抗剂)。
- 直接口服抗凝药在需要时进行治疗监测存在局限性,且儿童缺乏获批的逆转剂,引发安全性担忧。
- 直接口服抗凝药在成人中广泛适应症的安全性和有效性经验不断积累,但儿科经验稀少。
临床怎么用
- 作者分享管理4个场景的经验,涵盖适应症 appropriateness、特殊儿童人群使用、实验室监测考虑、抗凝药间转换、主要药物相互作用、围手术期管理和抗凝逆转。
局限性
- 直接口服抗凝药在需要时进行治疗监测存在局限性,且儿童缺乏获批的逆转剂,引发安全性担忧。
- 直接口服抗凝药在儿科患者中的累积经验稀少,尤其对合并慢性疾病者。
- 临床医生常需依赖自身经验并从成人数据外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The direct oral anticoagulants (DOACs) rivaroxaban and dabigatran are newly licensed for the treatment and prevention of venous thromboembolism (VTE) in children and mark a renaissance in pediatric anticoagulation management. They provide a convenient option over standard-of-care anticoagulants (heparins, fondaparinux, and vitamin K antagonists) because of their oral route of administration, child-friendly formulations, and significant reduction in monitoring. However, limitations related to therapeutic monitoring when needed and the lack of approved reversal agents for DOACs in children raise some safety concerns. There is accumulating experience of safety and efficacy of DOACs in adults for a broad scope of indications; however, the cumulative experience of using DOACs in pediatrics, specifically for those with coexisting chronic illnesses, is sparse. Consequently, clinicians must often rely on their experience for treating VTE and extrapolate from data in adults while using DOACs in children. In this article, the authors share their experience of managing 4 scenarios that hematologists are likely to encounter in their day-to-day practice. Topics addressed include (1) appropriateness of indication; (2) use for special populations of children; (3) considerations for laboratory monitoring; (4) transition between anticoagulants; (5) major drug interactions; (6) perioperative management; and (7) anticoagulation reversal.
引用
- Bhat RV, Young G, Sharathkumar AA, et al. How I treat pediatric venous thromboembolism in the DOAC era. Blood. 2024. PMID: 37390311. doi:10.1182/blood.2022018966
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。